BioMed Research International

Targeted Therapy in Hematological Malignancies: From Basic Research to Clinical Practice


Status
Published

Lead Editor

1Sun Yat-sen University, Zhuhai, China

2The University of Texas, Houston, USA

3Chinese Academy of Medical Science, Tianjin, China


Targeted Therapy in Hematological Malignancies: From Basic Research to Clinical Practice

Description

Targeted therapy has greatly changed the era of cancer treatment and has become one of the most rapidly evolving fields in both drug discovery and cancer treatment. The treatment of hematological malignancies has been a forerunner in targeted therapy, with one of the famous early hallmarks of successful targeted treatment by the use of all trans-retinoic acid in acute promyelocytic leukemia. Today, targeted therapy in hematological malignancies remains in the forefront of ongoing research. Over the past decades, many advances in hematology, genetics, epigenetics, biochemistry, chemistry, and other related disciplines have together greatly encouraged the development of targeted therapy. In tumor microenvironments, cancer cells and cancer stem cells, a multitude of different targets, including genes and their genetic or epigenetic modifiers, RNAs and noncoding RNAs, growth factors, receptors, enzymes, and signaling pathways involved in tumor initiation, growth and progression have been identified. Development of basic research boosted the improvement of targeted therapy in clinical studies. To date, targeted therapy has provided benefits for patients with hematological malignancies either as the first-line treatment or in combination with chemotherapy. Undoubtedly, in the near future, customized targeted therapy will play a more and more important role in hematological malignancies treatment.

In this special issue, we invite review and original research articles that describe new molecular targets, novel technologies, recent clinical trials, mechanism of drug resistance, and approaches to reduce side effects in hematological malignancies targeted therapy.

Potential topics include, but are not limited to:

  • Discovery and verification of novel molecular targets for hematological malignancies
  • Biomaterials, drug delivery, nanotechnology, and bioengineering in targeted therapy of hematological malignancies
  • Clinical trials of targeted therapy for hematological malignancies
  • Mechanism of drug resistance and strategies to overcome the resistance in hematological malignancies targeted therapy
  • Side effects of targeted therapy for hematological malignancies
  • Next generation sequencing, omics, and gene profiling in targeted therapy for hematological malignancies
  • Stem cells in hematological malignancies targeted therapy

Articles

  • Special Issue
  • - Volume 2015
  • - Article ID 157570
  • - Editorial

Targeted Therapy in Hematological Malignancies: From Basic Research to Clinical Practice

Haiqing Ma | Saradhi Mallampati | ... | Jin Wang
  • Special Issue
  • - Volume 2015
  • - Article ID 197241
  • - Research Article

MicroRNA181a Is Overexpressed in T-Cell Leukemia/Lymphoma and Related to Chemoresistance

Zi-Xun Yan | Zhong Zheng | ... | Wei-Li Zhao
  • Special Issue
  • - Volume 2015
  • - Article ID 217593
  • - Review Article

Targeted Therapies in Adult B-Cell Malignancies

Jean-François Rossi
  • Special Issue
  • - Volume 2015
  • - Article ID 895105
  • - Clinical Study

Rituximab as Single Agent in Primary MALT Lymphoma of the Ocular Adnexa

Ombretta Annibali | Francesca Chiodi | ... | Giuseppe Avvisati
  • Special Issue
  • - Volume 2015
  • - Article ID 648143
  • - Clinical Study

Clinical Safety and Immunogenicity of Tumor-Targeted, Plant-Made Id-KLH Conjugate Vaccines for Follicular Lymphoma

Daniel Tusé | Nora Ku | ... | John E. Butler-Ransohoff
  • Special Issue
  • - Volume 2015
  • - Article ID 927105
  • - Research Article

Subcutaneous Administration of Bortezomib in Combination with Thalidomide and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma Patients

Shenghao Wu | Cuiping Zheng | ... | Yuemiao Chen
BioMed Research International
 Journal metrics
Acceptance rate30%
Submission to final decision70 days
Acceptance to publication36 days
CiteScore2.410
Impact Factor2.197
 Submit

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.